Krystal Biotech, Inc. 2025 Q4 - Results - Earnings Call Presentation

Krystal Biotech released its Q4 2025 earnings presentation, detailing financial performance and operational milestones during its February 2026 earnings call. The company highlighted revenue growth driven by its lead gene therapy product, Vyjuvek, which secured expanded FDA approvals in late 2025 for additional dermatological indications. Clinical pipeline updates included Phase 3 trial progress for KB407, a potential treatment for cystic fibrosis, with topline data expected in mid-2026. Manufacturing expansions were announced, with a new GMP facility in Pittsburgh nearing completion to scale commercial production of its HSV-based therapies. Guidance for 2026 projected 40% year-over-year revenue growth, citing strong Vyjuvek adoption and anticipated regulatory milestones for its rare disease portfolio.